Int Neurourol J > Volume 27(3); 2023 > Article |
|
Characteristic | Total (n = 50,654) |
Group |
P-value | ||||||
---|---|---|---|---|---|---|---|---|---|
KTR (n = 165) | CKD5D (n = 5,905) | CKD1-4D (n = 11,559) | CKD-free (n = 33,025) | ||||||
Demography | |||||||||
Age (yr) | 69.6 ± 0.1 | 64.3 ± 0.5 | 68.5 ± 0.2 | 73.7 ± 0.1 | 68.3 ± 0.1 | < 0.001* | |||
40–49 | 2,163 (4.3) | 12 (7.3) | 257 (4.4) | 176 (1.5) | 1,718 (5.2) | < 0.001* | |||
50–59 | 7,399 (14.6) | 36 (21.8) | 948 (16.1) | 933 (8.1) | 5,482 (16.6) | ||||
60–69 | 15,118 (29.8) | 58 (35.2) | 1,869 (31.7) | 2,616 (22.6) | 10,575 (32.0) | ||||
70–79 | 15,635 (30.9) | 53 (32.1) | 1,915 (32.4) | 4,122 (35.7) | 9,545 (28.9) | ||||
≥ 80 | 10,339 (20.4) | 6 (3.6) | 916 (15.5) | 3,712 (32.1) | 5,705 (17.3) | ||||
Sex | < 0.001* | ||||||||
Male | 27,389 (54.1) | 102 (61.8) | 3,428 (58.1) | 6,589 (57.0) | 17,270 (52.3) | ||||
Female | 23,265 (45.9) | 63 (38.2) | 2,477 (41.9) | 4,970 (43.0) | 15,755 (47.7) | ||||
Race | < 0.001* | ||||||||
White | 31,312 (61.8) | 106 (64.2) | 2,851 (48.3) | 7,177 (62.1) | 21,178 (64.1) | ||||
Black | 10,861 (21.4) | 37 (22.4) | 1,928 (32.7) | 2,762 (23.9) | 6,134 (18.6) | ||||
Hispanic | 4,146 (8.2) | 15 (9.1) | 632 (10.7) | 767 (6.6) | 2,732 (8.3) | ||||
Others | 4,335 (8.6) | 7 (4.2) | 494 (8.4) | 853 (7.4) | 2,981 (9.0) | ||||
Household income | < 0.001* | ||||||||
Q1 | 13,435 (26.9) | 46 (28.0) | 1,955 (33.6) | 3,134 (27.5) | 8,300 (25.5) | ||||
Q2 | 12,337 (24.7) | 38 (23.2) | 1,414 (24.3) | 2,904 (25.5) | 7,981 (24.5) | ||||
Q3 | 12,347 (24.7) | 47 (28.7) | 1,323 (22.7) | 2,893 (25.4) | 8,084 (24.9) | ||||
Q4 | 11,782 (23.6) | 33 (20.1) | 1,125 (19.3) | 2,469 (21.7) | 8,155 (25.1) | ||||
Missing | 753 | 1 | 88 | 159 | 505 | ||||
Primary payer | < 0.001* | ||||||||
Medicare/Medicaid | 37,948 (75.0) | 125 (75.8) | 4,823 (81.8) | 9,698 (84.0) | 23,302 (70.7) | ||||
Private including HMO | 11,012 (21.8) | 33 (20.0) | 917 (15.5) | 1,564 (13.5) | 8,498 (25.8) | ||||
Self-pay/no-charge/other | 1,627 (3.2) | 7 (4.2) | 158 (2.7) | 285 (2.5) | 1,177 (3.6) | ||||
Missing | 67 | 0 | 7 | 12 | 48 | ||||
HSCT | 6,954 (13.7) | 31 (18.8) | 555 (9.4) | 1,083 (9.4) | 5,285 (16.0) | < 0.001* | |||
CCI | < 0.001* | ||||||||
0 | 18,439 (36.4) | 54 (32.7) | 1,447 (24.5) | 2,576 (22.3) | 14,362 (43.5) | ||||
1–3 | 27,823 (54.9) | 93 (56.4) | 3,540 (59.9) | 7,006 (60.6) | 17,184 (52.0) | ||||
≥4 | 4,392 (8.7) | 18 (10.9) | 918 (15.5) | 1,977 (17.1) | 1,479 (4.5) | ||||
Hospital bed size | < 0.001* | ||||||||
Small | 8,578 (16.9) | 19 (11.5) | 931 (15.8) | 2,056 (17.8) | 5,572 (16.9) | ||||
Medium | 13,312 (26.3) | 41 (24.8) | 1,656 (28.0) | 3,262 (28.2) | 8,353 (25.3) | ||||
Large | 28,764 (56.8) | 105 (63.6) | 3,318 (56.2) | 6,241 (54.0) | 19,100 (57.8) | ||||
Location/teaching status | < 0.001* | ||||||||
Rural | 3,296 (6.5) | 10 (6.1) | 280 (4.7) | 885 (7.7) | 2,121 (6.4) | ||||
Urban nonteaching | 9,784 (19.3) | 33 (20.0) | 1,270 (21.5) | 2,527 (21.9) | 5,954 (18.0) | ||||
Urban teaching | 37,574 (74.2) | 122 (73.9) | 4,355 (73.8) | 8,147 (70.5) | 24,950 (75.5) | ||||
Hospital region | < 0.001* | ||||||||
Northeast | 10,430 (20.6) | 25 (15.2) | 1,157 (19.6) | 2,098 (18.2) | 7,150 (21.7) | ||||
Midwest | 11,848 (23.4) | 33 (20.0) | 1,273 (21.6) | 3,040 (26.3) | 7,502 (22.7) | ||||
South | 19,320 (38.1) | 74 (44.8) | 2,426 (41.1) | 4,380 (37.9) | 12,440 (37.7) | ||||
West | 9,056 (17.9) | 33 (20.0) | 1,049 (17.8) | 2,041 (17.7) | 5,933 (18.0) |
Continuous variables are presented as mean±standard error and performed by PROC SURVEYMEANS statement; categorical variables are presented as unweighted counts (weighted percentage) and performed by PROC SURVEYFREQ statement.
MM, multiple myeloma; CKD, chronic kidney disease; PSM, propensity-score matching; KTR, kidney transplant recipient; CKD5D, stage 5 CKD; CKD1-4D, stage 1-4 CKD; HMO, health maintenance organization; HSCT, hematopoietic stem cell transplantation; CCI, Charlson Comorbidity Index.
Continuous variables are presented as mean±standard error and performed by PROC SURVEYMEANS statement; categorical variables are presented as unweighted counts (weighted percentage) and performed by PROC SURVEYFREQ statement.
MM, multiple myeloma; CKD, chronic kidney disease; PSM, propensity-score matching; KTR, kidney transplant recipient; CKD5D, stage 5 CKD; CKD1-4D, stage 1-4 CKD; HMO, health maintenance organization; HSCT, hematopoietic stem cell transplantation; CCI, Charlson Comorbidity Index.
Variable | Total (n=1,930) |
Group |
P-value | |||||
---|---|---|---|---|---|---|---|---|
KTR (n=164) | CKD5D (n=583) | CKD1-4D (n=590) | CKD-free (n=593) | |||||
Outcomes | ||||||||
In-hospital mortality | 93 (4.8) | 7 (4.3) | 36 (6.2) | 26 (4.4) | 24 (4.0) | 0.307 | ||
Unfavorable dischargea) | 333 (18.1) | 19 (12.1) | 106 (19.4) | 115 (20.4) | 93 (16.3) | 0.039 | ||
Prolonged LOSa) | 449 (24.4) | 35 (22.3) | 155 (28.3) | 127 (22.5) | 132 (23.2) | 0.070 | ||
Major complications, any | 1,024 (53.1) | 90 (54.9) | 308 (52.8) | 324 (54.9) | 302 (50.9) | 0.512 | ||
CVA | 83 (4.3) | 7 (4.3) | 26 (4.5) | 27 (4.6) | 23 (3.9) | 0.946 | ||
AMI | 67 (3.5) | 8 (4.9) | 21 (3.6) | 18 (3.1) | 20 (3.4) | 0.679 | ||
Respiratory failure | 315 (16.3) | 25 (15.2) | 102 (17.5) | 102 (17.3) | 86 (14.5) | 0.456 | ||
Pneumonia | 353 (18.3) | 34 (20.7) | 100 (17.2) | 100 (16.9) | 119 (20.1) | 0.343 | ||
Sepsis | 399 (20.7) | 43 (26.2) | 111 (19.0) | 130 (22.0) | 115 (19.4) | 0.122 | ||
Severe infection | 89 (4.6) | 10 (6.1) | 29 (5.0) | 25 (4.2) | 25 (4.2) | 0.692 | ||
DVT/PE | 112 (5.8) | 7 (4.3) | 38 (6.5) | 32 (5.4) | 35 (5.9) | 0.666 | ||
Mechanical ventilation | 132 (6.8) | 13 (7.9) | 44 (7.5) | 38 (6.4) | 37 (6.2) | 0.721 |
Categorical variables are presented as unweighted counts (weighted percentage) and performed by PROC SURVEYFREQ statement.
MM, multiple myeloma; CKD, chronic kidney disease; PSM, propensity-score matching; KTR, kidney transplant recipient; CKD5D, stage 5 CKD; CKD1-4D, stage 1-4 CKD; LOS, length of stay; CVA, cerebrovascular accident; AMI, acute myocardial infarction; DVT, deep vein thrombosis; PE, pulmonary embolism.
Outcome |
Group |
||||
---|---|---|---|---|---|
KTR | CKD5D | CKD1-4D | CKD-free | ||
In-hospital mortality | 1.06 (0.45–2.47) | 1.56 (0.94–2.60) | 1.09 (0.63–1.89) | Ref. | |
Unfavorable dischargea) | 0.70 (0.43–1.15) | 1.23 (0.91–1.66) | 1.31 (0.98–1.75) | Ref. | |
Prolonged LOSa) | 0.95 (0.64–1.42) | 1.31 (1.01–1.70)* | 0.96 (0.74–1.24) | Ref. | |
Major complications | |||||
CVA | 1.10 (0.42–2.88) | 1.16 (0.65–2.07) | 1.19 (0.68–2.08) | Ref. | |
AMI | 1.47 (0.67–3.22) | 1.07 (0.59–1.94) | 0.90 (0.49–1.64) | Ref. | |
Respiratory failure | 1.06 (0.66–1.71) | 1.25 (0.91–1.71) | 1.23 (0.90–1.68) | Ref. | |
Pneumonia | 1.04 (0.68–1.59) | 0.82 (0.62–1.09) | 0.81 (0.62–1.07) | Ref. | |
Sepsis | 1.48 (1.02–2.14)* | 0.98 (0.73–1.30) | 1.17 (0.90–1.54) | Ref. | |
Severe infection | 1.48 (0.70–3.12) | 1.19 (0.69–2.06) | 1.01 (0.59–1.72) | Ref. | |
DVT/PE | 0.71 (0.33–1.54) | 1.11 (0.70–1.77) | 0.91 (0.58–1.45) | Ref. | |
Mechanical ventilation | 1.29 (0.68–2.45) | 1.23 (0.79–1.91) | 1.03 (0.66–1.62) | Ref. |
Values are presented as odds ratio (95% confidence interval) using logistic regressions with PROC SURVEYLOGISTIC statement.
KTR, kidney transplant recipient; CKD, chronic kidney disease; MM, multiple myeloma; CKD5D, stage 5 CKD; CKD1-4D, stage 1-4 CKD; LOS, length of stay; CVA, cerebrovascular accident; AMI, acute myocardial infarction; DVT, deep vein thrombosis; PE, pulmonary embolism; ref., reference.